Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy

Kocher, Madison; Sharma, Anand; Garrett‐Mayer, Elizabeth; Ravenel, James G.

doi:10.1097/rct.0000000000000653

Cited by 5 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, our study demonstrated stronger correlations between SUV values and PET/MRI than between those values and CT [29]. Tumor volume and SUV values are considered prognostic factors-increased values of both are associated with a higher risk of death [30,31]. Biologically, larger tumors have higher metabolic activity and therefore, higher SUV values indicate a worse prognosis [32].…”

Section: Discussionmentioning

confidence: 53%

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Samołyk-Kogaczewska¹,

Sierko

Dziemiańczyk-Pakieła

et al. 2020

Cancers

View full text Add to dashboard Cite

(1) Background: The novel hybrid of positron emission tomography/magnetic resonance (PET/MR) examination has been introduced to clinical practice. The aim of our study was to evaluate PET/MR usefulness in preoperative staging of head and neck cancer (HNC) patients (pts); (2) Methods: Thirty eight pts underwent both computed tomography (CT) and PET/MR examination, of whom 21 pts underwent surgical treatment as first-line therapy and were further included in the present study. Postsurgical tissue material was subjected to routine histopathological (HP) examination with additional evaluation of p16, human papillomavirus (HPV), Epstein-Barr virus (EBV) and Ki67 status. Agreement of clinical and pathological T staging, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of CT and PET/MR in metastatic lymph nodes detection were defined. The verification of dependences between standardized uptake value (SUV value), tumor geometrical parameters, number of metastatic lymph nodes in PET/MR and CT, biochemical parameters, Ki67 index, p16, HPV and EBV status was made with statistical analysis of obtained results; (3) Results: PET/MR is characterized by better agreement in T staging, higher specificity, sensitivity, PPV and NPV of lymph nodes evaluation than CT imaging. Significant correlations were observed between SUVmax and maximal tumor diameter from PET/MR, between SUVmean and CT tumor volume, PET/MR tumor volume, maximal tumor diameter assessed in PET/MR. Other correlations were weak and insignificant; (4) Conclusions: Hybrid PET/MR imaging is useful in preoperative staging of HNC. Further studies are needed.

show abstract

Section: Discussionmentioning

confidence: 53%

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Samołyk-Kogaczewska¹,

Sierko

Dziemiańczyk-Pakieła

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In addition to its value on clinical staging, at least some data suggest that it has role in predicting outcome [5, 6]. Tumor maximum standardized uptake value (SUV max ), a measure of cellular metabolic activity of the tumor, defined by PET-CT was reported to be an independent predictor of survival and relapse in early-stage NSCLC.…”

mentioning

confidence: 99%

Pretreatment SUV max Value for Predicting Outcome in Stage III NSCLC Patients Receiving Concurrent Chemoradiotherapy

Yaprak

Özçelik

Gemici

et al. 2019

North Clin Istanbul

View full text Add to dashboard Cite

OBJECTIVE: Stage III disease accounts for approximately one-fourth of all non-metastatic non-small cell lung cancer (NSCLC). The patients who are not candidates for curative resection are offered concomitant chemoradiotherapy. In this subgroup, which is difficult to manage, studies that address the role of PET-CT to predict outcome measures specifically for stage III NSCLC receiving concurrent chemoradiotherapy may help better risk stratification. This study aimed to assess whether baseline PET maximum standardized uptake value (SUV max ) value in stage III NSCLC treated with concurrent chemoradiotherapy would independently identify patients with high risk of progression and death. METHODS: The study population consisted of patients aged 18 years or more with unresectable stage III histologically or cytologically proven NSCLC who received concurrent chemoradiotherapy. From 2007 to 2014, medical records of patients admitted to our institution were retrospectively analyzed. Pretreatment PET-CT SUV max values were recorded for each patient. These values were categorized as low or high according to the median SUV max measure of the study population. RESULTS: A total of 175 patients were analyzed. The median follow-up time was 23 months (range 6–109). The PET-CT SUV max values ranged from 3.5 to 46 with a median value of 14. The median overall survival was 25 months in SUV max <14 and 18 months in SUV max ≥14 group (p=0.023). The median progression-free survival was 16 months in SUV max <14 and 11 months in SUV max ≥14 group (p=0.033). Multivariate analysis revealed that both PET-CT SUV max value (p<0.001) and age (p=0.016) were independent significant predictors for overall survival (OS). CONCLUSION: The results of this study involving patients with stage III NSCLC receiving concurrent chemoradiotherapy provide evidence that suggests that high values of pretreatment SUV max , an indicator of metabolic tumor burden, predicted a higher risk of disease progression and death.

show abstract

“…Recently, some predictors have been reported to be associated with OS after SBRT, such as cardiac dose (Tembhekar et al 2017 ), mean lung dose (Dupic et al 2020 ), biologically effective dose (BED) of the prescription and maximum dose (Stahl et al 2016 ; Tateishi et al 2021 ), pre-treatment FDG-PET standardized uptake values (Kocher et al 2018 ), and pre-treatment hemoglobin level (Shaverdian et al 2016 ). Radiomics, a non-invasive technology that converts medical images into a high-dimensional mineable feature space via high-throughput quantitative feature extraction (Bera et al 2022 ; Gillies et al 2016 ; Lambin et al 2012 , 2017 ; Reuze et al 2018 ), has been introduced for the prediction of treatment responses, patient stratification, and prognosis for lung cancer patients in recent years (Chen et al 2017 , 2023 ; Constanzo et al 2017 ; Coroller et al 2015 ; Huang et al 2016 ; Lee et al 2017 ; Li et al 2018 ; Mattonen et al 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Developing a clinical-radiomic prediction model for 3-year cancer-specific survival in lung cancer patients treated with stereotactic body radiation therapy

Huang,

Wang,

Lin

2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The study aims to develop and validate a combined model for predicting 3-year cancer-specific survival (CSS) in lung cancer patients treated with stereotactic body radiation therapy (SBRT) by integrating clinical and radiomic parameters. Methods Clinical data and pre-treatment CT images were collected from 102 patients treated with lung SBRT. Multivariate logistic regression and the least absolute shrinkage and selection operator were used to determine the clinical and radiomic factors associated with 3-year CSS. Three prediction models were developed using clinical factors, radiomic factors, and a combination of both. The performance of the models was assessed using receiver operating characteristic curve and calibration curve. A nomogram was also created to visualize the 3-year CSS prediction. Results With a 36-month follow-up, 40 patients (39.2%) died of lung cancer and 62 patients (60.8%) survived. Three clinical factors, including gender, clinical stage, and lymphocyte ratio, along with three radiomic features, were found to be independent factors correlated with 3-year CSS. The area under the curve values for the clinical, radiomic, and combined model were 0.839 (95% CI 0.735–0.914), 0.886 (95% CI 0.790–0.948), and 0.914 (95% CI 0.825–0.966) in the training cohort, and 0.757 (95% CI 0.580–0.887), 0.818 (95% CI 0.648–0.929), and 0.843 (95% CI 0.677–0.944) in the validation cohort, respectively. Additionally, the calibration curve demonstrated good calibration performance and the nomogram created from the combined model showed potential for clinical utility. Conclusion A clinical-radiomic model was developed to predict the 3-year CSS for lung cancer patients treated with SBRT.

show abstract

Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy

Abstract: Both increased tumor size and metabolic activity are associated with increased risk of death. Combining size and metabolic activity together is superior for predicting 2-year survival and identifying patients for whom survival is statistically worse.

Cited by 5 publications

References 18 publications

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients

Pretreatment SUV max Value for Predicting Outcome in Stage III NSCLC Patients Receiving Concurrent Chemoradiotherapy

Developing a clinical-radiomic prediction model for 3-year cancer-specific survival in lung cancer patients treated with stereotactic body radiation therapy

Contact Info

Product

Resources

About